Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders
Launched by SPANISH FOUNDATION FOR NEUROMETRICS DEVELOPMENT · Apr 11, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
tDCS will be applied to 90 children diagnosed with ASD with Mu activity in one of their two temporal lobes and to another 90 children tDCS will not be applied but rather conventional treatments such as the Denver method, etc., in addition to collecting their electroencephalograms in eyes open condition, evoked potentials will be performed. with Mismatch Negativity paradigm to calculate the P300 wave every 25 sessions with a rest of 5-6 weeks between every 25 sessions and the changes in voltage and frequency of the EEG will be analysed using FFT \& PSD, as well as the latencies and amplitude...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age between 7 and 15 years old
- • Diagnosis: PDD, ASD or PANDAS
- • Have genetic alterations with geneticist reports like: mutation, random mating between organisms, random fertilization or crossing over (or recombination) between chromatids of homologous chromosomes during meiosis.
- • Natural birth without caesarean or complications
- • Normal Pregnancy
- Exclusion Criteria:
- • Head Trauma
- • Brain Injuries like meningitis or encephalitis, including SaRS, Herpes or MERS infections
- • Epilepsy
- • Rare Diseases with Auto-Immune Disease
- • Rare diseases with Endocrinology problems
- • Fever or Biochemical problems in the First Blood Test (First Visit)
- • Vaccines Reactions
About Spanish Foundation For Neurometrics Development
The Spanish Foundation for Neurometrics Development is a leading organization dedicated to advancing research and innovation in neurometrics, a field that integrates neuroscience and quantitative analysis to enhance understanding of neurological conditions. Committed to fostering collaboration between academic institutions, healthcare providers, and industry partners, the foundation aims to develop cutting-edge diagnostic tools and therapeutic interventions. By supporting clinical trials and promoting the translation of research findings into clinical practice, the foundation plays a pivotal role in improving patient outcomes and advancing the field of neurology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Liverpool, Merseyside, United Kingdom
Liverpool, Merseyside, United Kingdom
Patients applied
Trial Officials
Jean Neville, MD
Study Director
New Remedies Ltd
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported